30-JAN-2007
CeNeRx BioPharma Initiates Human Trials of RIMA Antidepressant
CeNeRx BioPharma Initiates Human Trials of RIMA Antidepressant
13-Dec-05 :
CeNeRx BioPharma Appoints Chief Medical Officer
CeNeRx BioPharma Appoints Chief Medical Officer
RESEARCH TRIANGLE PARK, NC, December 13, 2005 -- CeNeRx BioPharma, Inc., a start up
biopharmaceutical company focused on developing new therapeutics for central nervous
system disorders, is pleased to announce the addition of Atul C. Pande, MD as Chief
Medical Officer.
biopharmaceutical company focused on developing new therapeutics for central nervous
system disorders, is pleased to announce the addition of Atul C. Pande, MD as Chief
Medical Officer.
Leading research scientist to head CeNeRx development
29-Nov-05:
CeNeRx Announces $18.5 Million Series A Financing
CeNeRx Announces $18.5 Million Series A Financing
RESEARCH TRIANGLE PARK, NC, November 29, 2005 -- CeNeRx BioPharma, Inc., a
start up bio-pharmaceutical company focused on developing new therapeutics
for disorders of the central nervous system, today announced the completion of
$18.5 million in series A financing.
start up bio-pharmaceutical company focused on developing new therapeutics
for disorders of the central nervous system, today announced the completion of
$18.5 million in series A financing.
Start-up earns Triangle’s largest Q4 funding and 4th largest financing of 2005
1-Nov-05:
CeNeRx Announces License Agreement with Krenitsky Pharmaceuticals
CeNeRx Announces License Agreement with Krenitsky Pharmaceuticals
RESEARCH TRIANGLE PARK, NC, November 1, 2005 -- CeNeRx BioPharma, Inc., a
start up bio-pharmaceutical company focused on developing new therapeutics
for disorders of the central nervous system, and Krenitsky Pharmaceuticals Inc.
(KPI) today announced the licensing agreement of KPI's RIMA (reversible
inhibitors of monoamine oxidase) antidepressant series.
start up bio-pharmaceutical company focused on developing new therapeutics
for disorders of the central nervous system, and Krenitsky Pharmaceuticals Inc.
(KPI) today announced the licensing agreement of KPI's RIMA (reversible
inhibitors of monoamine oxidase) antidepressant series.
Strategic partnership to develop and deliver medicines for the future
RESEARCH TRIANGLE PARK, NC, January 30, 2007 -- CeNeRx BioPharma, Inc., a clinical stage
company developing and commercializing innovative treatments for diseases of the central
nervous system, today announced the initiation of human clinical trials of Tyrima™, CeNeRx’s
new drug candidate with a triple mechanism of action for the treatment of depression and
anxiety. Tyrima (formerly CX157) is a member of a novel class of drugs known as reversible
inhibitors of monoamine oxidase A, or RIMA.
company developing and commercializing innovative treatments for diseases of the central
nervous system, today announced the initiation of human clinical trials of Tyrima™, CeNeRx’s
new drug candidate with a triple mechanism of action for the treatment of depression and
anxiety. Tyrima (formerly CX157) is a member of a novel class of drugs known as reversible
inhibitors of monoamine oxidase A, or RIMA.
First Subjects Dosed in Phase l Trial of Triple Action Agent Tyrima™
13-MAR-07:
CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third
Generation RIMA Antidepressant
CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third
Generation RIMA Antidepressant
RESEARCH TRIANGLE PARK, NC, March 13, 2007 -- CeNeRx BioPharma, Inc., a clinical stage
company developing and commercializing innovative treatments for diseases of the central
nervous system, today announced top-line results from a Phase I clinical trial of Tyrima™...
company developing and commercializing innovative treatments for diseases of the central
nervous system, today announced top-line results from a Phase I clinical trial of Tyrima™...
Tyrima™ Demonstrates Good Safety Profile and Excellent Pharmacokinetic Properties
30-May-07:
CeNeRx Announces Agreement with PharmaNess Neuroscience to Develop Novel
Cannabinoid Compounds
CeNeRx Announces Agreement with PharmaNess Neuroscience to Develop Novel
Cannabinoid Compounds
RESEARCH TRIANGLE PARK, NC, May 30, 2007 -- CeNeRx BioPharma, Inc., a biopharmaceutical
company developing and commercializing innovative treatments for diseases of the central
nervous system, today announced it has signed an agreement with PharmaNess
Neuroscience giving CeNeRx the rights to a series of novel cannabinoid compounds...
company developing and commercializing innovative treatments for diseases of the central
nervous system, today announced it has signed an agreement with PharmaNess
Neuroscience giving CeNeRx the rights to a series of novel cannabinoid compounds...
Strategic Partnership Gives CeNeRx Rights to Develop and Commercialize Extensive Cannabinoid
Pipeline for Pain and Other Disorders
Pipeline for Pain and Other Disorders
16-OCT-07:
CeNeRx Biopharma Adds Dr. Daniel Burch as Chief Medical Officer
CeNeRx Biopharma Adds Dr. Daniel Burch as Chief Medical Officer
Former GlaxoSmithKline Neurosciences Head Brings Broad Research & Development
Expertise to Help Advance the Company’s CNS Portfolio
Expertise to Help Advance the Company’s CNS Portfolio
RESEARCH TRIANGLE PARK, NC, October 16, 2007 -- CeNeRx BioPharma, Inc., a
biopharmaceutical company developing and commercializing innovative treatments for
diseases of the central nervous system, today announced the addition of Daniel Burch,
M.D., M.B.A. as Executive Vice President of R&D and Chief Medical Officer...
biopharmaceutical company developing and commercializing innovative treatments for
diseases of the central nervous system, today announced the addition of Daniel Burch,
M.D., M.B.A. as Executive Vice President of R&D and Chief Medical Officer...
16-JAN-08:
CeNeRx BioPharma Announces Successful Completion of Phase I Clinical Program for
Novel Antidepressant Agent Tyrima™
CeNeRx BioPharma Announces Successful Completion of Phase I Clinical Program for
Novel Antidepressant Agent Tyrima™
Tyrima Exhibits Excellent Safety Profile and Favorable Pharmacokinetics in Phase I Studies
RESEARCH TRIANGLE PARK, NC, January 16, 2008 -- CeNeRx BioPharma, Inc., a clinical stage
company developing and commercializing innovative treatments for diseases of the central
nervous system, today announced the successful completion of the Phase l clinical
program for Tyrima™, its lead candidate for the treatment of depression and anxiety.
Tyrima is a selective and reversible member of a novel class of drugs known as RIMAs...
company developing and commercializing innovative treatments for diseases of the central
nervous system, today announced the successful completion of the Phase l clinical
program for Tyrima™, its lead candidate for the treatment of depression and anxiety.
Tyrima is a selective and reversible member of a novel class of drugs known as RIMAs...
12-MAY-08:
CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development
CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development
Former GSK Clinical Development Head Brings Over 20 Years of Clinical and Product
Development Expertise to the Company’s CNS Portfolio
Development Expertise to the Company’s CNS Portfolio
RESEARCH TRIANGLE PARK, NC, May 12, 2008 -- CeNeRx BioPharma, Inc., a
biopharmaceutical company developing and commercializing innovative treatments for
diseases of the central nervous system (CNS), today announced the appointment of Dr.
Mahnaz Asgharnejad as Vice President of Clinical Development. Dr. Asgharnejad will play a
central role in expanding CeNeRx’s clinical development capabilities and advancing the
clinical trials of CeNeRx’s investigational drugs. Previously, Dr. Asgharnejad spent more
than two decades at GlaxoSmithKline (GSK), where she held clinical development
positions of increasing responsibility, most recently as GSK’s Senior Director of Psychiatry
Clinical Development and Product Strategy.
biopharmaceutical company developing and commercializing innovative treatments for
diseases of the central nervous system (CNS), today announced the appointment of Dr.
Mahnaz Asgharnejad as Vice President of Clinical Development. Dr. Asgharnejad will play a
central role in expanding CeNeRx’s clinical development capabilities and advancing the
clinical trials of CeNeRx’s investigational drugs. Previously, Dr. Asgharnejad spent more
than two decades at GlaxoSmithKline (GSK), where she held clinical development
positions of increasing responsibility, most recently as GSK’s Senior Director of Psychiatry
Clinical Development and Product Strategy.
22-JUL-08:
CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant
Agent Tyrima™ Using Innovative Brain Imaging Study
CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant
Agent Tyrima™ Using Innovative Brain Imaging Study
State-of-the-Art PET Study Confirms Tyrima Exhibits Excellent Drug-Like Properties.
--Results Support Initiation of Phase II Clinical Trials--
--Results Support Initiation of Phase II Clinical Trials--
RESEARCH TRIANGLE PARK, NC, July 22, 2008 -- CeNeRx BioPharma, Inc., a clinical stage
company developing and commercializing innovative treatments for diseases of the central
nervous system, today announced plans to advance its lead candidate Tyrima™ into Phase
II trials for the treatment of depression and anxiety. This milestone is based on the
positive results of the Tyrima Phase I program reported earlier this year and the recent
completion of PET brain imaging studies showing that Tyrima penetrates the CNS and
exhibits excellent pharmacokinetic and pharmacodynamic properties.
company developing and commercializing innovative treatments for diseases of the central
nervous system, today announced plans to advance its lead candidate Tyrima™ into Phase
II trials for the treatment of depression and anxiety. This milestone is based on the
positive results of the Tyrima Phase I program reported earlier this year and the recent
completion of PET brain imaging studies showing that Tyrima penetrates the CNS and
exhibits excellent pharmacokinetic and pharmacodynamic properties.
